Amicus Therapeutics (FOLD) Osake Kurssi
Amicus Therapeutics Kurssi
Viimeisten 18 vuoden aikana Amicus Therapeuticsn liikevaihto kasvoi 38,6 % vuodessa ja ylsi 634,21 M USD:een. Amicus Therapeuticsn nettomarginaali −4,3 % on noussut verrattuna −82,0 %:iin muutama vuosi sitten. Amicus Therapeuticsn 12 kuukauden konsensustavoitehinta on 14,79 USD, noin yli kurssia 2,1 %. 14 analyytikosta 6 suosittaa ostoa — kokonaiskonsensus on Pidä.
Amicus Therapeutics osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Amicus Therapeutics liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Amicus Therapeutics -osakkeesta
The business model of Amicus Therapeutics Inc. revolves around developing advanced therapies for rare and orphan diseases. The company focuses on utilizing its Chaperone-Advanced Replacement Therapy (CHART™) platform to deliver enzyme replacement therapies (ERTs) for individuals suffering from lysosomal storage disorders (LSDs). As a biopharmaceutical company, Amicus Therapeutics aims to address unmet medical needs through innovative drug research and development. By leveraging their expertise in protein misfolding and folding, Amicus Therapeutics aims to improve the lives of patients with genetic diseases.
Amicus Therapeutics Inc is primarily active in the biotechnology industry.
The main competitors of Amicus Therapeutics Inc in the market include companies such as Vertex Pharmaceuticals, BioMarin Pharmaceutical, and Sanofi Genzyme.
Amicus Therapeutics Inc is a biopharmaceutical company headquartered in Cranbury, New Jersey. Founded in 2002, Amicus Therapeutics focuses on developing advanced therapies for rare and orphan diseases. The company's innovative approach is based on the principles of personalized medicine, utilizing breakthrough science and technology. Over the years, Amicus Therapeutics has established itself as a leader in the field, with a strong dedication to improving the lives of patients with devastating genetic diseases. Through its robust research and development efforts, Amicus Therapeutics has successfully advanced several potential treatments, striving to bring hope and transformative therapies to those in need.
Amicus Therapeutics Inc has achieved significant milestones in its journey. Some notable accomplishments include the approval of Galafold, a breakthrough therapy for Fabry disease, by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, the company has made remarkable progress in developing innovative therapies for rare genetic diseases such as Pompe disease and other lysosomal storage disorders. Amicus Therapeutics Inc has successfully conducted clinical trials and obtained positive results, showcasing their commitment to advancing medical science and improving patients' lives. Their unwavering dedication has positioned them as a leading player in the biopharmaceutical industry.
Amicus Therapeutics Inc is primarily present in the United States.
Amicus Therapeutics Inc represents values of innovation, dedication, and patient-centricity. With a corporate philosophy focused on delivering life-changing therapies, Amicus strives to improve the lives of individuals with rare and devastating diseases. The company is committed to advancing science, developing transformative medicines, and ensuring access to those therapies for patients in need. Amicus fosters a collaborative and compassionate approach, working closely with patient advocacy groups, healthcare professionals, and regulatory authorities to make a meaningful impact in the lives of the communities it serves.
Analyytikot asettavat tällä hetkellä Amicus Therapeutics-osakkeelle keskimääräisen tavoitehinnan 15,81 USD (mediaani: 14,79 USD), mikä merkitsee +9,1 % viimeisimpään hintaan verrattuna. Konsensus perustuu 14 analyytikkoarvioon.
14 analyytikkoa arvioi tällä hetkellä Amicus Therapeutics-osaketta: 6 suosittaa ostoa, 8 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Amicus Therapeutics-yhtiöltä 753,69 M USD liikevaihtoa ja 0,36 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Amicus Therapeutics-osake noteerataan hintaan 13,20 EUR (14,49 USD).
Amicus Therapeutics-osake (FOLD) on listattuna 6 pörssissä, muun muassa: NASDAQ (FOLD), London (0HF9.L), Frankfurt (AM6.F), München (AM6.MU), Düsseldorf (AM6.DU).
Amicus Therapeutics Inc (Nasdaq: FOLD) aims to develop and manufacture novel therapies for people with rare and severe diseases. The biotechnology company, based in Cranbury, New Jersey, USA, focuses on researching and developing drugs that aim to influence the natural metabolism of proteins in the body to treat diseases caused by mutations in genes. The business model of Amicus Therapeutics is based on the discovery and development of therapies specialized in treating rare and severe diseases. The company works closely with patients and their families to gain a better understanding of the needs and challenges of these patient groups. Amicus utilizes a proprietary technology platform called Chaperon-Advanced Replacement Therapy (CHART), which allows for the treatment of Ectopic Glycosylation Disorders (EGS) by replacing faulty proteins produced by gene mutations with functional and stable therapeutics. Amicus Therapeutics specializes in the following three areas: 1. Fabry disease: A rare lysosomal metabolic disorder where the Alpha-Galactosidase-A enzyme is not produced normally due to mutations in the GLA gene. Amicus has developed Galafold, the first oral medication for treating Fabry disease, which aims to stabilize the faulty protein. 2. Pompe disease: A lysosomal storage disease characterized by a deficiency of enzymes that help in breaking down glycogen. This results in an accumulation of glycogen in various tissues and organs. Amicus has developed ATB200/AT2221, a combined therapy of enzyme replacement therapy and chaperone therapy aimed at correcting the enzyme deficiency caused by mutation. 3. Phenylketonuria (PKU): A metabolic disorder where an individual lacks the ability to metabolize phenylalanine. This leads to an accumulation of phenylalanine in the body, which can cause impairments to the central nervous system. Amicus has a pipeline of therapeutics in development for treating PKU, including a chaperone platform and an enzyme replacement therapy. Amicus Therapeutics collaborates closely with medical centers, patient organizations, and research institutions to develop innovative therapies for rare and severe diseases. The company is committed to enhancing the effectiveness and safety of medications, helping to improve the quality of life for affected individuals. By focusing on rare and severe diseases, Amicus Therapeutics can serve a niche and position itself as an innovator in the biotechnology industry. Overall, Amicus Therapeutics' business model has the potential to achieve significant medical advancements while also being profitable. The company is well-positioned to continue developing innovative therapies for rare and severe diseases that can improve the lives of patients and their families.
odotettu liikevaihto Amicus Therapeutics on 753,69 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Amicus Therapeutics on 111,97 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Amicus Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä 40,68. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Amicus Therapeutics-osakkeen arvostusta.
Amicus Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 6,04. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Amicus Therapeutics-osakkeen arvostuskennuslukuna.
Amicus Therapeutics:n Eulpool-laatuscore on 4/10.
Amicus Therapeutics:n ISIN on US03152W1099. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Amicus Therapeutics:n WKN on A0MSMZ. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Amicus Therapeutics:n ticker on FOLD. Tämä pörssinoteeraus käytetään Amicus Therapeutics-osakkeiden kauppaan pörssissä.
Amicus Therapeutics osake
Amicus Therapeutics vertaisryhmä
Amicus Therapeutics Ticker
Amicus Therapeutics FIGI
Kaikki tunnusluvut ja syvällinen analyysi Amicus Therapeutics:sta
Meidän osakeanalyysimme Amicus Therapeutics-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Amicus Therapeutics:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: